Research progress in drug therapy of juvenile idiopathic arthritis

World J Pediatr. 2022 Jun;18(6):383-397. doi: 10.1007/s12519-022-00530-8. Epub 2022 Apr 1.


Background: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children. With the gradual expansion of the incidence of JIA in the population, the pathogenesis and treatment of JIA were further explored and analyzed, and JIA has achieved some success in drug therapy.

Data sources: A systemic literature search was conducted on PubMed, Cochrane Library, EMBASE, ISI Web of Science, the US National Institutes of Health Ongoing Trials Register, and the EU Clinical Trials Register. Through the searching of clinical trials of JIA in recent years, we summarized the progress of the clinical treatment of JIA.

Results: The main treatment drugs for JIA include non-steroidal anti-inflammatory drugs, glucocorticoids, disease-modifying antirheumatic drugs and biological agents. So far, a variety of biological agents targeting the cytokines and receptors involved in its pathogenesis have been gradually approved for JIA in many countries. The application of biological agents in JIA showed good efficacy and safety, bringing unprecedented experience to children and adolescents with JIA.

Conclusions: The potential and advantages of biologic agents in the treatment of JIA are significant, and the application of biologic agents in the treatment of JIA will be more and more common.

Keywords: Juvenile idiopathic arthritis; Progress; Treatment.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Antirheumatic Agents* / therapeutic use
  • Arthritis, Juvenile* / drug therapy
  • Biological Factors / therapeutic use
  • Child
  • Glucocorticoids / therapeutic use
  • Humans
  • Incidence
  • Treatment Outcome


  • Antirheumatic Agents
  • Biological Factors
  • Glucocorticoids